CAMP4 THERAPEUTICS CORPORATION (CAMP)
NGM · Healthcare · Biotechnology
$4.19
-0.71%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$217.6M
Shares Outstanding
51.9M
P/S (TTM)
55.3x
Exchange
NGM
Currency
USD
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 1.5M | 795K | 348K | 1.3M |
| Operating Income | -13.0M | -13.2M | -12.8M | -13.1M |
| Net Income | -12.6M | -15.1M | -40.3M | -18.3M |
| Diluted EPS | $-0.62 | $-0.55 | $nan | $-0.32 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 350K | 652K | 3.5M |
| Operating Income | -45.0M | -51.9M | -53.1M | -52.1M |
| Net Income | -44.2M | -49.3M | -51.8M | -80.4M |
| Diluted EPS | $-3.64 | $-4.07 | $-11.04 | $nan |